The US Food and Drug Administration has approved a new drug to treat adults with chronic myeloid leukaemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia (ALL) – three months ahead of schedule. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
